NO references on this page

of

Sheet

PTO/SB/08A (09-06) Approved for use through 03/31/2007 OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to resp ond to a collection of information unless it contains a valid OMB control num Complete if Known Substitute for form 1449/PTO Application Number 10/574.994 Filing Date October 5, 2004 (I.A.) INFORMATION DISCLOSURE First Named Inventor Betty A. Diamond STATEMENT BY APPLICANT Art Unit to be determined (Use as many sheets as necessary) Examiner Name to be determined

Attorney Docket Number 96700/1120

U. S. PATENT DOCUMENTS Ocument Number Publication Date Name of Patentee or Pag Rela , Columns, Lines, Where Examiner MM-DD-YYYY Initials* Applicant of Cited Document ant Passages or Relevant Figures Appear Kind Code² (# known) TIS ŪS-US-US-US US US-US US-US-IIS. US-US I IS US. US.

Examiner City Foreign Patent Document FOREIGN PATENT DOCUMENTS Published Patents or Published

Transition of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (light by the USFTO 6 process) an application. Certificentiality is governed by 35 USC. 122 and 37 CFR 1.14. This collection is estimated to task 2 hours to obgetive the collection of the USFTO. The way redepending upon the individual case. Any combents on the flowest or the collection of the collection of

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTC/SB/08B (09-06)
Approved for use through 03/31/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OM8 control number.

	Complete if Known		
Application Number	10/574,994		
Filing Date	October 5, 2004 (I.A.)		
First Named Inventor	Betty A. Diamond		
Art Unit	to be determined		
Examiner Name	to be determined		
Attorney Docket Number	96700/1120		
	Filing Date First Named Inventor Art Unit Examiner Name		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	ABDEL-RAHMAN A. et al., "Disruption of the Blood-Brain Barrier and Neuronal Cell Death in Cingulate Cortex, Dentate Gyrus, Thalamus, and Hypothalamus in a Rat Model of Gulf-War Syndrome"; Neurobiology of Disease, 2002, Vol. 10, No. 3, pp 306-26.	
	2	ACR AD HOC COMMITTEE ON NEUROPSYCHIATRIC LUPUS NOMENCLATURE, "The American College of Rheumatology Nomenclature and Case Definitions for Neuropsychiatric Lupus Syndromes", Arthritis & Rheumatism, 1999, Vol. 42, No. 4, pp 599-608.	
	3	BREY R.L. et al., "Neuropsychiatric syndromes in lupus - Prevalence using standardized definitions"; Neurology, 2002, Vol. 58, No. 9, pp 1214-20.	
	4	DEGIORGIO L.A. et al., "A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus"; Nature Medicine, 2001, Vol. 7, No. 1, no. 118,93	
	5	DELL'ALIBERA-JOVILIANO R. et al., "Kinins and Cytokines in Plasma and Cerebrospinal Fluid of Patients with Neuropsychiatric Lupus"; The Journal of Rheumatology, 2003, Vol. 30, No. 3, pp 485-92.	
	6	DENBURG S.D. and DENBURG J.A., "Cognitive Dysfunction in Systemic Lupus Erythematosus," in Systemic Lupus Erythematosus, Third Edition, Robert G. Lahita, Editor, Academic Press, San Diego, CA, 1999, pp 611-29.	
	7	ELKON K.B. et al., "Antiribosomal Antibodies in Systemic Lupus Erythematosus"; Rheumatic Disease Clinics of North America, 1992, Vol. 18, No. 2, pp 377-90.	
	8	ESPOSITO P. et al., "Corticotropin-Releasing hormone and Brain Mast Cells Regulate Blood-Brain-Barrier Permeability Induced by Acute Stress"; The Journal of Pharmacology and Experimental Therapeutics, 2002, Vol. 303, No. 3, pp 1061-66.	
	9	FRIEDMAN A. et al., "Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response"; Nature Medicine, 1996, Vol. 2, No. 12, pp. 1382-85.	
	10	GAYNOR B. et al., "Peptide inhibition of glomerular deposition of an anti-DNA antibody"; PNAS, 1997, Vol. 94, pp 1955-60.	

Signature Considered Considered PEXAMMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through clastion if not in conformance and not considered, include copy of this form with next communication to applicant.

Examiner

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

^{1.} Applicant indexing only in ordination number (optional). 2 Applicant is to place a check mark here if English happage Transition is attached.

This collection of information is required by 37 CFR 1.8.1. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.4.1. This collection is estimated to take 2 hours to complete, including a pathering, preprint, and submitting the completed application from the the USPTO. Then will very depending upon the individual case. Any comments on the amount of time you require to complete in publication from the USPTO. Then will very depending upon the individual case. Any comments on the amount of time you require to complete this public on the other time in individual case. Any comments on the amount of time you require to complete this public will be a complete and complete and complete and complete any comments of the amount of the your require to complete the public which is the file of the public will be a complete and the public will b

PTO/SB/08B (09-06) Approved for use through 03/31/2007. OMB 0561-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subering	e for form 1449/PTO			Complete if Known			
Cubacia	50035000 101 101 101 101 101 101 101 101 101		Application Number	10/574,994	٦		
INFO	DRMATION	DIS	CLOSURE	Filing Date	October 5, 2004 (I.A.)	٦	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Betty A. Diamond		
(Use as many sheets as necessary)				Art Unit	to be determined		
	(Use as many sne	1013 83 110	cessary,	Examiner Name	to be determined		
Sheet	3	of	4	Attorney Docket Number	96700/1120	フ	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	11	HANLY J.G. et al., "Brain Pathology in Systemic Lupus Erythematosus"; The Journal of Rheumatology, 1992, Vol. 19, No. 5, pp 732-41.	
	12	HUGHES G.R.V. et al., "The Anticardiolipin Syndrome"; The Journal of Rheumatology, 1986, Vol. 13, No. 3, pp 486-9.	
	13	JOHN G.R. et al., "Cytokines: Powerful Regulators of Glial Cell Activation"; The Neuroscientist, 2003, Vol. 9, No. 1, pp 10-22.	
	14	JONGEN P.J.H. et al., Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system*; Acta Neurologica Scandinavica, 2000, Vol. 101, No. 2, pp 116-21.	
	15	KAO C-H. et al., 'The role of FDG-PET, HMPAO-SPET and MRI in the detection of brain involvement in patients with systemic lupus erythematosus'; European Journal of Nuclear Medicine, 1999, Vol. 26, No. 2, pp 129-34.	
	16	KOZORA E. et al., "Magnetic Resonance Imaging Abnormalities and Cognitive Deficits in Systemic Lupus Enythematosus Patients Without Overt Central Nervous System Disease", Arthritis & Rheumatism, 1998, Vol. 41, No. 1, pp 41-47.	
	17	LERITZ E. et al., "Neuropsychological Functioning and Its Relationship to Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus", Journal of Clinical and Experimental Neurophychology, 2002, Vol. 24, No. 4, pp 527-33.	
	18	LERITZ E. et al., "Subcortical" cognitive impairment in patients with systemic lupus erythematosus"; Journal of the International Neuropsychological Society, 2000, Vol. 6, No. 7, pp 821-5.	
	19	LIM M.K. et al., "Systemic Lupus Erythematosus: Brain MR Imaging and Single-Voxel Hydrogen 1 MR Spectroscopy"; Radiology, 2000, Vol. 217, No. 1, pp43-49.	
	20	NOMURA K. et al., "Asymptomatic Cerebrovascular Lesions Detected by Magnetic Resonance Imaging in Patients with Systemic Lupus Erythematosus Lacking a History of Neuropsychiatric Events"; Internal Medicine, 1999, Vol. 38, No. 10, pp 785-95.	

Signature	Considered	
*EXAMINER: Initial if reference considered, whether or not citation is	e in conformance with MPEP 609. Draw line through citation if not in conforman	ne and not

Examiner

considered. Include copy of this form with next communication to applicant,

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This processor is required by 7 CPR 1.98. The filmomation is required to obtain or retain a benefit by the public which is to file (and by the USPTO for process) an application. Confidentiality is governed by 35 U.S.C. 123 and 37 CPR 1.14. This collection is estimated to take 3 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of sine you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1469, Nezardis, VA 22331-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

PTO/SB/08B (09-06)

Approved for use through 03/31/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. OEPARTMENT OF COMMERCE

$\overline{}$	e for form 1449/PTO			e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
	Sassification (Simples)		Application Number	10/574,994		
			CLOSURE	Filing Date	October 5, 2004 (I.A.)	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Betty A. Diamond	
(Use as many sheets as necessary)				Art Unit	to be determined	
(coo ao many oncoo ao nocasaa y			oceasary)	Examiner Name	to be determined	
Sheet	4	of	4	Attorney Docket Number 96700/1120		

. . .

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	NYLÉN K. et al., "Cerebrospinal Fluid neurofilament and Glial Fibrillary Acidic Protein in Patients With Cerebral Vasculitis"; Journal of Neuroscience Research, 2002, Vol. 67, No. 6, pp 844-51.	
	22	PUTTERMAN C. and DIAMOND B. "Immunization with a Peptide Surrogate for Double- stranded DNA (dsDNA) Induces Autoantibody Production and Renal Immunoglobulin Deposition"; Journal of Experimental Medicine, 1998, Vol. 188, No. 1, pp 29-38.	
	23	SABET A. et al., "Neurometabolite Markers of Cerebral Injury in the Antiphospholipid Antibody Syndrome of Systemic Lupus Erythematosus"; Stroke, 1998, Vol. 29, No. 11, pp 2254-60.	
	24	SANNA G. et al., "Central nervous system involvement in systemic lupus erythematosis: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations"; Lupus, 2000, Vol. 9, No. 8, pp573-83.	
	25	SHARMA A. et al., "Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-reactive antigens"; Rheumatology, 2003, Vol. 42, pp 453-60.	
	26	SIBBITT, JR. W.L. et al., "Neuroimaging in Neuropsychiatric Systemic Lupus Erythematosus"; Arthritis & Rheumatism, 1999, Vol. 42, No. 10, pp 2026-38.	
	27	XAIO H. et al., "Effect of LPS on the permeability of the blood-brain barrier to insulin"; Brain Research, 2001, Vol. 896, No. 1,2, pp 36-42.	

Examiner Signature /Ronald Niebauer/ Date Considered 01/07/2010				
Signature / HORIZIO NIEDZUEI/ Considered 01/07/2010	Examiner	(Deneld Michause)	Date	01/07/2010
	Signature	/Horiaid Niebauer/	Considered	01/07/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{**}EXAMENE** Initial of referencia considered, whether or not citation is an accolormance with MEPE 959. Draw line through citation if not in conformance and not a "Applicants" to update or update of the property of the public which is to file (and by the USPTO to locate or the property of the public which is to file (and by the USPTO to proceed) any application. Confidentiality is governed by 32 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to proceed) any application. Confidentiality is governed by 32 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to proceed) any application. Confidentiality is governed by 32 CFR 1.98. The Information is retained to the information in the information in the confidence of the Information of Information of the Information of Inf Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.